Pharmafile Logo

What Is the RDI-Lancet Commission for Rare Disease and What Will It Achieve?

December 23, 2025 |  

Christy Rohani-Montez, Medscape’s Rare Disease Education Lead recently spoke with Dr Lucy McKay, CEO, and Megan Pullein, Strategic Operations Officer from the UK-based charity Medics for Rare Disease (MfRD). We discussed their involvement in the recently formed RDI-Lancet Commission for Rare Diseases, a global initiative aimed at developing evidence-based recommendations to improve the lives of the 400 million people living with rare diseases worldwide.

lucy                           Picture1megan

Lucy McKay                                                  Megan Pullein
CEO                                                                Strategic Operations Officer
Medics for Rare Disease                            Medics for Rare Disease

Christy: It’s lovely to be speaking with one of our favourite partners in rare disease, Medics for Rare Disease! Lucy, and Megan, could you start by introducing yourselves, Medics for Rare Disease, and its mission?

Lucy: Absolutely, I’m Dr Lucy McKay, the CEO of Medics for Rare Disease, and our vision is simple: equitable healthcare for everyone. Our mission is to shape a medical profession that can provide timely diagnosis and excellent care to people living with rare diseases.

Megan: I’m Megan Pullein, and I’m the Strategic Operations Officer at Medics for Rare Disease. My primary role is to help manage our work with the RDI-Lancet Commission, specifically for Working Group 2, which Lucy Co-Chairs.

Christy: What are the Lancet Commissions, and what is the RDI-Lancet Commission for Rare Diseases?

Megan: The Lancet Commissions are in-depth research initiatives that tackle urgent and complex global health issues. They gather experts from around the world to collaborate on solutions, which are then published in the renowned medical journal. The vision for this specific commission is to make rare diseases visible globally, ensuring that every person is seen, heard, and cared for, no matter where they live. The goal is to produce actionable recommendations that any government can take and implement within their society.

Christy: I understand that the commission is divided into 5 working groups. What is the focus of each?

Lucy: Before breaking down the groups, it’s important to state the golden thread that runs through all of this: human rights. The entire commission is fundamentally about achieving equity for patients around the world.

Megan: That leads perfectly into Working Group 1, which is focused on visibility for human rights. This is the core of the commission. Working Group 2, which we are leading, focuses on visibility for social justice. These are the 2 overarching themes. The other groups are more specific: Group 3 is looking at data and metrics; Group 4 is tackling visibility within healthcare systems, particularly the diagnostic odyssey; and Group 5 is focused on clinical pathways and trials.

Christy: Where does the work for each group start, and where does it end?

Lucy: We’re working in 3 phases. For example, in Working Group 2, first is a comprehensive literature review to answer the question: is social justice being achieved for people living with rare disease? If so, how? And if not, why not?

The second phase is generating new evidence. We want to fill the gaps we find in the literature, especially from geographical and demographical sources that are currently missing. We have a lofty goal of trying to represent advocates from every UN-recognized country, starting with the places from which we hear no voices.

The final phase will be to consolidate this evidence into concrete recommendations.

Christy: What do you find most exciting about RDI-Lancet Commission?

Lucy: For The Lancet to even highlight Rare Disease is a major milestone in history. What excites me is that this project forces us to pull back to focus on the individual. We constantly have to ask, for example, How is this recommendation going to help someone in rural Chile? It moves the conversation beyond tech, molecules, and industry chatter. Tech doesn’t matter to people if they can’t access it or are being treated without the respect every human being deserves.

It allows us to establish a global standard of provision for the rare disease community and will help shape The World Health Organisation’s Global Action Plan for Rare Disease. We hope that in the future there will be greater standardisation and transparency in how nations care for rare diseases. This will empower the rare disease community to understand what they are entitled to, the barriers to access and to demand accountability.

Christy: Thank you so much Lucy and Megan, it’s exciting to see this research moving forward, and we’re all looking forward to seeing the forthcoming publications.

For more information on the RDI-Lancet Commission:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00211-9/abstract

About Medscape Education

Medscape Education (medscape.org) is the leading destination for continuous professional development, consisting of more than 30 specialty-focused destinations offering thousands of free CME and CE courses for physicians, nurses, and other healthcare professional

This content was provided by Medscape Education

Company Details

 Latest Content from  Medscape Education 

The Power of Disease Awareness in Infectious Disease Education at IDWeek 2023

Medscape Education had one of its biggest conferences of the year with IDWeek 2023, hosting six educational symposia and presenting five scientific posters highlighting the outcomes of recent infectious disease...

Hear From Her: Announcing The Women in Healthcare Leadership Series Podcast

On the 8th November 2023, Medscape will launch the first episode of their new podcast: the Women in Healthcare Leadership Podcast Series.This insightful series was designed to elevate and empower...

Medscape Education Invites Listeners to ‘Hear From Her’ With New Women in Healthcare Leadership Podcast Series

Medscape Education has launched their new podcast: the Women in Healthcare Leadership Podcast Series. The series, hosted by Medscape Education employees, features women in leadership roles across industry as well...

Sharing Outcomes in MS at ECTRIMS 2023

During ECTRIMS 2023 congress, the Medscape Education Global team will be on site to present a poster of their educational outcomes.The poster, Virtual Patient Simulation Improves Neurologists’ Performance in Making...

Shining a Light on Current Topics in Oncology

The Medscape Oncology team will be on the road again, this time in Madrid, Spain for ESMO 2023. This year, the team will be sharing education with a deep impact...

Disseminating Outcomes and Impact in Berlin

The Medscape Education Global team is looking forward to a busy time in Berlin at the EADV Congress 2023. During the congress, Medscape will be presenting five posters examining the...

Medscape Education’s Large Presence at IDWeek 2023

Medscape are powering education and disease state awareness in infectious diseases at #IDWeek 2023

Contagious Conversations: Exploring Infectious Disease in the Digital Age

As the world of medicine continues to evolve, it's crucial to stay ahead of the curve. In this dynamic era, digital communications have emerged as a driving force in discussions...

Presenting Outstanding Outcomes from HCP Education in Multiple Myeloma at IMS in Athens

From September 27-30, members of the Medscape Education Global team were in Athens, Greece sharing 5 posters at the International Myeloma Society Annual Meeting, 2023.The posters presented the outcomes and...

Impacting Lives with Rare Disease Education

Education on rare diseases is crucial. Estimates suggest there are approximately 10,000 rare diseases, with 263–446 million people affected worldwide.Since its launch in September 2022, the Medscape Pathways in Rare...